Economic evaluation of Annao Pills combined with antihypertensive drugs in treatment of primary hypertension:a study based on decision tree model
The purpose of this study was to evaluate the economics of Annao Pills combined with antihypertensive drugs in the treat-ment of primary hypertension in the Chinese medical setting.TreeAge pro 2018 was used for cost-effect analysis and sensitivity analysis of the two treatment regimens.The intervention time of the simulation model was 2 weeks.The cost parameters were derived from Yaozhi.com,and the effect parameters were based on Meta-analysis of randomized controlled trial(RCT)involving Annao Pills.The experimental group was treated with Annao Pills combined with anti-hypertensive drugs(nifedipine controlled-release tablets + losartan potassium tablets),and the control group was treated with anti-hypertensive drugs(nifedipine controlled-release tablets + losartan po-tassium tablets).The basic analysis showed that the incremental cost-effect ratio(ICER)of the two groups was 2 678.67 yuan,which was less than 7.26%of the per capita disposable income in 2022.That is,compared with anti-hypertensive drugs alone,Annao Pills combined with antihypertensive drugs cost 2 678.67 yuan more for each additional patient with primary hypertension.The results of sensitivity analysis verified the robustness of the basic analysis results.The probability sensitivity results showed that when the patient's personal willingness to pay the price was higher than 2 650 yuan,the probability of the regimen in the experimental group was higher,which was consistent with the results of the basic analysis.In conclusion,when the price was higher than 2 650 yuan,Annao Pills combined with anti-hypertensive drugs was more economical than anti-hypertensive drugs alone in terms of improving the response rate of the patients with primary hypertension.
NETL
NSTL
万方数据
